Oxypro 80mg is a high-strength, licensed generic and proprietary oral prolonged-release pharmaceutical preparation containing oxycodone hydrochloride<\/b> (equivalent to reference innovator preparations such as OxyContin, Longtec, and Reltebon). Chemically designated as $(5R,9R,13S,14S)\\text{-4,5}\\alpha\\text{-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one hydrochloride}$<\/span>, oxycodone is a semi-synthetic thebaine-derived phenanthrene opioid alkaloid. Structurally, it is characterized by a morphinan skeleton featuring an ether bridge between carbon-4 and carbon-5, a methoxy substituent at carbon-3, a tertiary hydroxyl group at carbon-14 (which significantly enhances $\\mu$<\/span>-opioid receptor affinity and blunts peripheral histamine release compared to codeine), and a ketone group at carbon-6. Its empirical molecular formula as the hydrochloride salt is $\\text{C}_{18}\\text{H}_{21}\\text{NO}_4\\cdot\\text{HCl}$<\/span>, with an average molecular weight of $351.82\\text{ g\/mol}$<\/span> (unconjugated oxycodone base: $315.36\\text{ g\/mol}$<\/span>).<\/p>\n The commercial presentation of Oxypro 80mg in the United Kingdom consists of round, biconvex, film-coated prolonged-release tablets (characteristically colored yellow to green depending on the authorized marketing authorization holder, often debossed with “80” on one face). The prolonged-release matrix incorporates a hydrophilic or lipophilic polymer-based dissolution retardant system (typically ammonio methacrylate copolymer, hypromellose, or stearyl alcohol) combined with excipients such as lactose monohydrate, povidone, talc, magnesium stearate, and titanium dioxide (E171). This formulation controls the release kinetics of the active pharmaceutical ingredient over a 12-hour period<\/b>, preventing the immediate release of the substantial $80\\text{ mg}$<\/span> opioid payload.<\/p>\n Within the United Kingdom regulatory framework:<\/p>\n Medicinal Classification:<\/b> Categorized as a Prescription Only Medicine (POM)<\/b> governed by the Human Medicines Regulations 2012.<\/p>\n<\/li>\n Controlled Drug Scheduling:<\/b> Under the Misuse of Drugs Act 1971, oxycodone is scheduled as a Class A controlled substance<\/b>. Under the Misuse of Drugs Regulations 2001, Oxypro 80mg sits in Schedule 2 (CD POM)<\/b>. Prescriptions are subject to strict statutory requirements:<\/p>\n Maximum legal validity of 28 days<\/b> from the date of signature.<\/p>\n<\/li>\n Mandatory declaration of the formulation, strength, dosing regimen, and total quantity written in both words and figures<\/b>.<\/p>\n<\/li>\n Subject to Safe Custody requirements<\/b> (must be stored in a secured, locked Controlled Drugs cabinet conforming to BS 2881 standards within pharmacies and hospital wards) and mandatory entry into the statutory Controlled Drugs Register.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n NHS Formulary Status:<\/b> Catalogued in the British National Formulary (BNF) and listed on the NHS Drug Tariff, reserved strictly for specialized Step 3 opioid therapy.<\/p>\n<\/li>\n<\/ul>\n Because an individual $80\\text{ mg}$<\/span> tablet represents a massive opioid dose (clinically bioequivalent to approximately $120\\text{ to }160\\text{ mg}$<\/span> of oral morphine), Oxypro 80mg is heavily targeted for diversion on black markets (often referred to as “Oxy 80s” or “Green Beans”). Crushing, chewing, dissolving, or nasal\/intravenous administration completely destroys the sustained-release matrix\u2014a catastrophic pharmacological phenomenon known as dose-dumping<\/b>\u2014releasing the entire dose immediately. In opioid-naive individuals, this dose routinely causes rapid, fatal respiratory arrest. Furthermore, illicit markets are flooded with counterfeit “Oxy 80” tablets pressed with lethal nitazene analogues<\/b> (e.g., protonitazene, metonitazene) or illicit fentanyl.<\/p>\n The pharmacodynamic profile of oxycodone is characterized by potent, high-affinity agonism at central and peripheral opioid receptors:<\/p>\n $\\mu$<\/span>-Opioid (MOP) Receptor Agonism:<\/b> Oxycodone functions as a pure agonist displaying high intrinsic efficacy and selectivity at human $\\mu$<\/span>-opioid receptors located across the dorsal horn of the spinal cord, periaqueductal gray, thalamus, and cortex:<\/p>\n Receptor coupling to inhibitory $G_{\\alpha i\/o}$<\/span> proteins inhibits adenylyl cyclase, decreasing intracellular cyclic adenosine monophosphate (cAMP).<\/p>\n<\/li>\n Presynaptically, it closes voltage-gated N-type calcium ($Ca^{2+}$<\/span>) channels, arresting the vesicular exocytosis of primary nociceptive neurotransmitters (substance P, glutamate, and CGRP).<\/p>\n<\/li>\n Postsynaptically, it opens G-protein-coupled inwardly rectifying potassium (GIRK) channels. The resulting potassium efflux hyperpolarizes postsynaptic projection neurons, stabilizing resting membrane potentials below the threshold needed to generate action potentials.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Secondary $\\kappa$<\/span>-Opioid (KOP) Agonism Controversy:<\/b> Experimental studies historically suggested meaningful interaction with $\\kappa$<\/span>-opioid receptors (accounting for its notable clinical efficacy in neuropathic and visceral pain). However, modern radioligand binding and functional assays confirm that its primary analgesia, physical dependence, and adverse effect profile are mediated almost entirely through the $\\mu$<\/span>-receptor, with low-affinity interaction at $\\kappa$<\/span>– and $\\delta$<\/span>-receptors.<\/p>\n<\/li>\n Direct Intrinsic Activity vs. Active Metabolites:<\/b> Unlike codeine, oxycodone does not require metabolic bioactivation to produce clinical analgesia<\/b>. Intact parent oxycodone accounts for approximately $80\\%$<\/span> of its total central analgesic effect. While CYP2D6 converts a fraction into oxymorphone<\/b> (which has an affinity for $\\mu$<\/span>-receptors roughly 10-fold higher than oxycodone), circulating concentrations of oxymorphone remain exceptionally low, meaning clinical pharmacodynamics are driven predominantly by the parent drug.<\/p>\n<\/li>\n Relative Potency and Morphine Equivalence:<\/b> Oxycodone is a high-potency Step 3 opioid. In clinical opioid rotations:<\/p>\n Oral oxycodone is approximately 1.5 to 2 times as potent as oral morphine<\/b>.<\/p>\n<\/li>\n A single Oxypro 80mg tablet provides analgesic exposure equivalent to $120\\text{ to }160\\text{ mg}$<\/span> of oral morphine sulphate<\/b> across a 12-hour window.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Respiratory Depression and Enteric Motility:<\/b> Agonism within the pontomedullary respiratory centers (the pre-B\u00f6tzinger complex) blunts chemoreceptor sensitivity to hypercapnia ($\\text{PaCO}_2$<\/span>) and hypoxia, causing severe bradypnea. In the gastrointestinal tract, stimulation of myenteric $\\mu$<\/span>-receptors arrests propulsive peristalsis and increases sphincter tone, universally causing constipation.<\/p>\n<\/li>\n<\/ul>\n Oxypro 80mg is indicated strictly for patients who are already opioid-tolerant<\/b> and require high-dose Step 3 opioid management under BNF and NICE guidelines:<\/p>\n Severe Cancer-Related Pain:<\/b><\/p>\n Indicated for the control of severe, intractable chronic pain in malignant disease when non-opioids, weak opioids (Step 2), or lower-dose Step 3 opioids fail to provide adequate pain relief.<\/p>\n<\/li>\n Dosed strictly on a 12-hourly schedule<\/b> ($80\\text{ mg}$<\/span> every 12 hours). Breakthrough pain is managed using immediate-release oral oxycodone (e.g., OxyNorm liquid or capsules), calculated at one-sixth to one-tenth of the total 24-hour baseline dose (e.g., $15\\text{ to }25\\text{ mg}$<\/span> immediate-release PRN).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Severe Non-Malignant Chronic Pain (Strictly Specialist-Initiated):<\/b><\/p>\n Short-to-medium-term management of severe chronic pain (e.g., severe osteoarthritic destruction, advanced neuropathic syndromes, failed back surgery syndrome) refractory to multi-modal non-opioid strategies.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Strict Opioid Tolerance Prerequisite:<\/b><\/p>\n Oxypro 80mg is absolutely contraindicated in opioid-naive patients.<\/b><\/p>\n<\/li>\n Initiation is restricted exclusively to patients who have demonstrated tolerance by receiving stable, high-dose opioid therapy for at least one to two weeks (e.g., at least $60\\text{ mg}$<\/span> of oral morphine daily, $30\\text{ mg}$<\/span> of oral oxycodone daily, or an equianalgesic dose of another Step 3 opioid).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n NICE Guidance on Chronic Non-Cancer Pain (NG193):<\/b><\/p>\n NICE explicitly advises against the initiation of high-dose opioids for chronic primary pain due to lack of evidence for long-term functional improvement, high dependence liability, and the risk of opioid-induced hyperalgesia (OIH).<\/p>\n<\/li>\n Treatment must be guided by agreed functional goals, documented regular reviews, and clear exit\/tapering strategies.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n In non-medical, illicit contexts, Oxypro 80mg is sought for intense euphoric intoxication, emotional detachment, and profound somatic sedation. Recreational users tamper with the tablet (crushing to snort, or cooking for injection) to circumvent the extended-release matrix, which leads to high fatality rates from overdose.<\/p>\n The pharmacokinetic performance of Oxypro 80mg depends entirely on intact oral ingestion to maintain its biphasic, extended-release absorption profile:<\/p>\n $N$<\/span>-Demethylation via CYP3A4 (Major Route, $\\sim 80\\%$<\/span>):<\/b> The dominant metabolic pathway converts oxycodone into noroxycodone<\/b>. Noroxycodone is a very weak $\\mu$<\/span>-opioid agonist ($>10\\text{-fold}$<\/span> less potent than oxycodone) with poor blood-brain barrier penetration, contributing minimally to analgesia.<\/p>\n<\/li>\n $O$<\/span>-Demethylation via CYP2D6 (Minor Route, $\\sim 10\\%$<\/span>):<\/b> Converts oxycodone into oxymorphone<\/b>, a potent $\\mu$<\/span>-opioid agonist. Although oxymorphone possesses high receptor affinity, its circulating plasma concentrations are too low to significantly impact overall analgesia. Consequently, poor or extensive CYP2D6 metabolizer status does not alter therapeutic response in a clinically meaningful way.<\/p>\n<\/li>\n Secondary Reductions and Glucuronidation:<\/b> Phase II UDP-glucuronosyltransferases conjugate oxycodone and its metabolites into polar, inactive glucuronide conjugates cleared by the kidneys.<\/p>\n<\/li>\n Renal Clearance Dynamics:<\/b> Less than $10\\%$<\/span> of an administered dose is excreted unchanged in the urine. In patients with severe renal impairment (eGFR $<30\\text{ mL\/min\/1.73 m}^2$<\/span>), peak concentrations and total exposure ($AUC$<\/span>) increase by $40\\text{ to }60\\%$<\/span>, requiring dose adjustments and longer dosing intervals.<\/p>\n<\/li>\n<\/ol>\n Therapeutic administration provides profound analgesia and anxiolytic relief. However, extensive $\\mu$<\/span>-opioid receptor engagement across multiple organ systems produces a characteristic spectrum of adverse effects:<\/p>\n Gastrointestinal and Autonomic Effects (Very Common, $\\ge 1\/10$<\/span>):<\/b><\/p>\n Severe Constipation:<\/b> Occurs in up to $80\\%$<\/span> of long-term users. Opioid binding in the enteric plexus arrests intestinal peristalsis and secretomotor fluid transport. Tolerance does not develop; co-prescribing prophylactic stimulant and osmotic laxatives is clinically mandatory.<\/p>\n<\/li>\n Nausea and Vomiting: Direct chemical excitation of the chemoreceptor trigger zone (CTZ) in the area postrema.<\/p>\n<\/li>\n Xerostomia (dry mouth), dyspepsia, and biliary spasm (elevated biliary pressure via Sphincter of Oddi constriction).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Central Nervous System and Neuropsychiatric Toxicity (Common, $1\/100$<\/span> to $<1\/10$<\/span>):<\/b><\/p>\n Somnolence, daytime sedation, dizziness, headache, and cognitive clouding.<\/p>\n<\/li>\n Euphoria or paradoxical dysphoria, restlessness, and acute confusion (disproportionately observed in elderly patients).<\/p>\n<\/li>\n Muscle fasciculations, myoclonus, and hyperalgesia (associated with toxic metabolite accumulation at high doses).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Cutaneous Reactions:<\/b><\/p>\n Pruritus, flushing, and sweating. Oxycodone induces significantly less mast cell degranulation than morphine, but pruritus remains common due to central $\\mu$<\/span>-receptor mechanisms.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Severe, Emergent and Life-Threatening Hazards (Overdose & Dependence):<\/b><\/p>\n Catastrophic Central Respiratory Depression:<\/b> The primary cause of death. Suppression of the medullary pre-B\u00f6tzinger complex leads to severe bradypnea ($<8\\text{ breaths\/min}$<\/span>), progressive cyanosis, stupor advancing to coma, severe hypoxemia, hypercapnic acidosis, and fatal asystole.<\/p>\n<\/li>\n Dose-Dumping Toxicity:<\/b> If an Oxypro 80mg tablet is chewed, crushed, or dissolved, the entire $80\\text{ mg}$<\/span> payload is released immediately into systemic circulation ($C_{max}$<\/span> occurs within 30 to 45 minutes rather than 6 to 8 hours), precipitating rapid, fatal respiratory arrest even in partially tolerant individuals.<\/p>\n<\/li>\n Synergistic Depressant Collapse:<\/b> Co-ingestion with alcohol, benzodiazepines, or gabapentinoids (pregabalin, gabapentin)<\/b> dramatically amplifies medullary depression, causing rapid loss of consciousness, pulmonary aspiration, and fatal hypoxia.<\/p>\n<\/li>\n Rapid Physical Dependence and Severe Withdrawal:<\/b> Continuous exposure drives receptor uncoupling and compensatory upregulation of the cAMP cascade. Abrupt cessation triggers an acute withdrawal syndrome: intense autonomic hyperactivity (sinus tachycardia, hypertension, diaphoresis), severe gastrointestinal cramping, diarrhea, piloerection (“cold turkey”), pupil dilation (mydriasis), myalgias, and severe psychological distress.<\/p>\n<\/li>\n Counterfeit Nitazene Poisoning:<\/b> Black-market tablets sold as “Oxy 80” frequently contain synthetic nitazene opioids<\/b> (e.g., protonitazene, metonitazene, isotonitazene), which exhibit potencies tens to hundreds of times higher than morphine. Nitazenes cause rapid, severe respiratory arrest that requires massive, escalated doses of naloxone to reverse.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n Prescribing, titrating, and monitoring Oxypro 80mg mandates strict adherence to safety exclusions, metabolic drug-interaction screening, and Controlled Drugs governance:<\/p>\n Contraindications:<\/b><\/p>\n Opioid-Naive Patients:<\/b> Absolute, Life-Threatening Contraindication.<\/b> Ingestion of $80\\text{ mg}$<\/span> of oxycodone without pre-existing tolerance frequently precipitates fatal respiratory arrest.<\/p>\n<\/li>\n Severe Respiratory Depression:<\/b> Absolute contraindication in acute respiratory failure, severe chronic obstructive pulmonary disease (COPD), respiratory arrest, or acute severe asthma.<\/p>\n<\/li>\n Paralytic Ileus or Obstructive Bowel Disease:<\/b> Absolute contraindication due to risk of precipitating toxic megacolon or bowel perforation.<\/p>\n<\/li>\n Raised Intracranial Pressure (ICP) and Severe Head Injury:<\/b> Opioid-induced $\\text{CO}_2$<\/span> retention drives cerebral vasodilation, dangerously spiking intracranial pressure.<\/p>\n<\/li>\n Severe Hepatic Cirrhosis (Child-Pugh Class C):<\/b> Clearance of parent drug is severely blunted, leading to massive, uncontrolled drug accumulation.<\/p>\n<\/li>\n Concurrent Monoamine Oxidase Inhibitors (MAOIs):<\/b> Absolute contraindication during or within 14 days of MAOI therapy.<\/p>\n<\/li>\n Pregnancy and Breastfeeding:<\/b> Avoided during pregnancy unless essential (risks neonatal respiratory depression and neonatal opioid withdrawal syndrome [NOWS]); contraindicated in nursing mothers (oxycodone concentrates in breast milk, causing fatal infant sedation).<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Drug Interactions:<\/b><\/p>\n Potent Cytochrome P450 3A4 Inhibitors (e.g., Ketoconazole, Itraconazole, Clarithromycin, Erythromycin, Ritonavir, Grapefruit Juice):<\/i> \n
\n
2. Mechanism of Action and Pharmacodynamics<\/h2>\n
\n
\n
\n
3. Approved UK Clinical Indications and Therapeutic Scope<\/h2>\n
\n
\n
\n
\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n\n
\n Pharmacokinetic Parameter<\/strong><\/td>\n Value \/ Metric<\/strong><\/td>\n Clinical Interpretation<\/strong><\/td>\n<\/tr>\n<\/thead>\n\n \n Oral Bioavailability<\/b><\/span><\/td>\n $60\\text{ to }87\\%$<\/span><\/b><\/span><\/td>\n High and reliable compared to oral morphine ($20\\text{\u2013}40\\%$<\/span>).<\/span><\/td>\n<\/tr>\n \n Release Pattern \/ $T_{max}$<\/span><\/b><\/span><\/td>\n Biphasic: Initial peak at $1\\text{ to }3\\text{ hours}$<\/span><\/b>, broad second peak at $6\\text{ to }8\\text{ hours}$<\/span><\/b><\/span><\/td>\n Sustains constant therapeutic plasma concentrations over 12 hours.<\/span><\/td>\n<\/tr>\n \n Volume of Distribution ($V_{ss}$<\/span>)<\/b><\/span><\/td>\n $2.6\\text{ to }3.2\\text{ L\/kg}$<\/span><\/b><\/span><\/td>\n Extensive extravascular and central nervous system tissue distribution.<\/span><\/td>\n<\/tr>\n \n Plasma Protein Binding<\/b><\/span><\/td>\n $\\sim 45\\%$<\/span> (Moderate)<\/span><\/td>\n Bound primarily to human serum albumin; low risk of displacement interactions.<\/span><\/td>\n<\/tr>\n \n Primary Hepatic Enzymes<\/b><\/span><\/td>\n CYP3A4<\/b> ($\\sim 80\\%$<\/span>), CYP2D6<\/b> ($\\sim 10\\%$<\/span>)<\/span><\/td>\n High susceptibility to systemic CYP3A4 inhibitors and inducers.<\/span><\/td>\n<\/tr>\n \n Active Metabolites<\/b><\/span><\/td>\n Oxymorphone<\/b> (potent, low titer), Noroxycodone (weak)<\/span><\/td>\n Parent drug drives the overwhelming majority of clinical efficacy.<\/span><\/td>\n<\/tr>\n \n Elimination Route<\/b><\/span><\/td>\n Renal ($80\\%$<\/span>, unconjugated drug and metabolites)<\/span><\/td>\n Elimination is prolonged in moderate-to-severe renal failure.<\/span><\/td>\n<\/tr>\n \n Elimination Half-Life ($t_{1\/2}$<\/span>)<\/b><\/span><\/td>\n Apparent $t_{1\/2} \\approx \\mathbf{4.5\\text{ to }6.5\\text{ hours}}$<\/span><\/span><\/td>\n Prolonged by ongoing release from the polymer matrix (flip-flop kinetics).<\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Biotransformation Cascades<\/h3>\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
\n
\n
\n
\n
\n
6. Contraindications, Drug Interactions, and Clinical Precautions<\/h2>\n
\n
\n
\n